Edition:
United States

Endologix Inc (ELGX.OQ)

ELGX.OQ on NASDAQ Stock Exchange Global Select Market

5.25USD
15 Dec 2017
Change (% chg)

$0.05 (+0.96%)
Prev Close
$5.20
Open
$5.16
Day's High
$5.36
Day's Low
$5.05
Volume
478,324
Avg. Vol
177,347
52-wk High
$7.66
52-wk Low
$4.08

Latest Key Developments (Source: Significant Developments)

Endologix Q3 loss per share $0.17
Tuesday, 7 Nov 2017 04:01pm EST 

Nov 7 (Reuters) - Endologix Inc ::Endologix reports third quarter 2017 financial results.Sees FY 2017 gaap loss per share $0.91 to $0.93.Q3 loss per share $0.17.Sees FY 2017 revenue $181 million to $184 million.Q3 revenue $46 million versus I/B/E/S view $46.7 million.Q3 earnings per share view $-0.17 -- Thomson Reuters I/B/E/S.  Full Article

Endologix says operations not materially affected by Santa Rosa fires‍​
Thursday, 12 Oct 2017 06:24am EDT 

Oct 12 (Reuters) - Endologix Inc : :Comments on impact of the Santa Rosa fires impact on co's facility ‍​.Co's Santa Rosa, California-based facility that manufactures and develops its ovation product line is safe and secure.Says it operations have not been materially affected by the Santa Rosa fires.Endologix Inc says it resumed shipments from its Santa Rosa facility on Oct 10, following a brief delay, and plans to resume manufacturing soon.Endologix Inc says many of the company’s Santa Rosa employees have been adversely impacted by the fire.  Full Article

Endologix announces CE Mark approval for Nellix Endovascular Aneurysm Sealing System
Thursday, 21 Sep 2017 08:00am EDT 

Sept 21 (Reuters) - Endologix Inc :Endologix announces CE Mark approval for the Nellix Endovascular Aneurysm Sealing System with the refined indications for use.Endologix Inc - ‍Nellix is being studied in U.S. under an Investigational Device Exemption​.  Full Article

Endologix Q2 loss per share $0.20
Wednesday, 2 Aug 2017 04:01pm EDT 

Aug 2 (Reuters) - Endologix Inc :Endologix reports second quarter 2017 financial results.Sees FY 2017 GAAP loss per share $0.91 to $0.95.Q2 loss per share $0.20.Sees FY 2017 revenue $185 million to $190 million.Q2 revenue $48.6 million versus I/B/E/S view $47.6 million.Q2 earnings per share view $-0.18 -- Thomson Reuters I/B/E/S.FY2017 earnings per share view $-0.63, revenue view $195.1 million -- Thomson Reuters I/B/E/S.  Full Article

Partner Fund Management reports 6.4 pct passive stake in Endologix ‍​
Thursday, 1 Jun 2017 04:11pm EDT 

June 1 (Reuters) - Endologix Inc ::Partner fund management, l.p. Reports 6.4 percent passive stake in endologix inc as of may 22, 2017 - sec filing‍​.  Full Article

Endologix provides an update on the Nellix EVAS System
Wednesday, 17 May 2017 04:45pm EDT 

May 17 (Reuters) - Endologix Inc :Endologix provides an update on the Nellix Endovascular Aneurysm Sealing System U.S. regulatory status.Will collaborate with FDA over coming months on confirmatory clinical study protocol.To seek U.S. approval of Nellix EVAS System by conducting confirmatory clinical study with previously updated instructions for use, Gen2 device design.Anticipates beginning patient enrollment for the study in Q4 of this year with PMA approval estimated to occur in 2020.  Full Article

Endologix reports Q1 loss per share $0.26
Thursday, 4 May 2017 04:01pm EDT 

May 4 (Reuters) - Endologix Inc :Endologix reports first quarter 2017 financial results.Q1 loss per share $0.26.Q1 revenue $42.6 million versus I/B/E/S view $41.1 million.Q1 earnings per share view $-0.21 -- Thomson Reuters I/B/E/S.Sees FY 2017 revenue $193 million to $200 million.Sees FY 2017 revenue up 0 to 4 percent.Sees FY 2017 gaap loss per share $0.83 to $0.86.Endologix - Endologix reaffirms its previously issued revenue guidance and continues to anticipate 2017 revenue to be in range of $193 million to $200 million.Endologix Inc - total cash, cash equivalents, restricted cash and marketable securities were $36.0 million as of march 31, 2017.  Full Article

Endologix enters into $170 mln credit facility with Deerfield Management
Tuesday, 4 Apr 2017 06:00pm EDT 

Endologix Inc : Endologix enters into $170 million credit facility with Deerfield Management . Endologix Inc - Deerfield provided Endologix with $120 million of gross proceeds in funding . Endologix Inc - Endologix has agreed to pay Deerfield a yield enhancement payment equal to 2.25% of principal amount at time of funding . Endologix Inc - Outstanding principal accrues interest until maturity on April 2, 2023 at a rate of 6.87% per annum . Endologix - Under terms of revolving line of credit, endologix may borrow up to lesser of $50 million or its applicable borrowing base from time to time . Endologix Inc - Any outstanding principal under revolving line of credit will accrue interest at a rate equal to libor rate plus 4.60% . Endologix - To use about $52.5 million of proceeds from term loan to repurchase $53.1 million principal amount of outstanding 2.25% convertible senior notes due 2018 . Endologix - To enter into unwind agreement with Bank of America NA to unwind portion of capped call transactions in respect of notes to be repurchased .Endologix Inc - Revolving line of credit will replace Endologix's $50 million asset-based revolving line of credit with Midcap Financial Trust.  Full Article

Brown Capital reports a 10.58 pct passive stake in Endologix Inc
Tuesday, 7 Mar 2017 10:11am EST 

Endologix Inc :Brown Capital Management LLC reports a 10.58 percent passive stake in Endologix Inc as of Feb 28, 2017.  Full Article

Endologix reports Q4 loss per share of $0.30
Wednesday, 22 Feb 2017 04:05pm EST 

Endologix Inc : Endologix reports results for the fourth quarter and full year 2016 . Sees FY 2017 GAAP loss per share $0.70 to $0.76 . Q4 loss per share $0.30 . Sees FY 2017 revenue $193 million to $200 million . Sees FY 2017 revenue up 0 to 4 percent . Q4 revenue $47.5 million versus I/B/E/S view $48.7 million . Q4 earnings per share view $-0.19 -- Thomson Reuters I/B/E/S .FY2017 earnings per share view $-0.70, revenue view $199.5 million -- Thomson Reuters I/B/E/S.  Full Article

BRIEF-Endologix Q3 loss per share $0.17

* Q3 earnings per share view $-0.17 -- Thomson Reuters I/B/E/S Source text for Eikon: Further company coverage: